Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -41.20% is 75% above its 2-year average of -161.84%, near the high end of its 2-year range (-343.90%–-34.23%).
As of the fiscal period ended Tuesday, June 30, 2026. 70.52% above its 12-month average of -139.78%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -41.20%.
RETURN ON EQUITY (ROE)
-41.20%
RETURN ON EQUITY (ROE) AVG TTM
-139.78%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+70.52%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+1.93%
vs the sector median at left
Anteris Technologies Global Corp.
Market Cap
$688.40M
Return on Equity (ROE)
-41.20%
TTM Avg
-139.78%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$689.85M
Return on Equity (ROE)
-44.64%
TTM Avg
-42.57%
3Y Avg
32.15%
5Y Avg
-68.82%
Market Cap
$688.30M
Return on Equity (ROE)
-47.51%
TTM Avg
-32.80%
3Y Avg
-39.18%
5Y Avg
-31.37%
Market Cap
$684.40M
Return on Equity (ROE)
-405.51%
TTM Avg
42.95%
3Y Avg
-55.53%
5Y Avg
-60.37%
Market Cap
$683.91M
Return on Equity (ROE)
-113.05%
TTM Avg
-95.98%
3Y Avg
-72.88%
5Y Avg
-73.85%
Market Cap
$676.87M
Return on Equity (ROE)
-55.36%
TTM Avg
-93.85%
3Y Avg
-76.06%
5Y Avg
-67.62%
Market Cap
$682.79M
Return on Equity (ROE)
-44.63%
TTM Avg
-42.69%
3Y Avg
-38.09%
5Y Avg
-55.51%
Market Cap
$704.20M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
Market Cap
$709.36M
Return on Equity (ROE)
15.36%
TTM Avg
25.54%
3Y Avg
15.72%
5Y Avg
18.75%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $688.40M | -41.20% | -139.78% | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $689.85M | -44.64% | -42.57% | 32.15% | -68.82% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $688.30M | -47.51% | -32.80% | -39.18% | -31.37% |
| Verastem, Inc. (VSTM)vs › | $684.40M | -405.51% | 42.95% | -55.53% | -60.37% |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.91M | -113.05% | -95.98% | -72.88% | -73.85% |
| Solid Biosciences Inc. (SLDB)vs › | $676.87M | -55.36% | -93.85% | -76.06% | -67.62% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $682.79M | -44.63% | -42.69% | -38.09% | -55.51% |
| Cytek Biosciences, Inc. (CTKB)vs › | $704.20M | -25.03% | -10.49% | -5.87% | -23.97% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.36M | 15.36% | 25.54% | 15.72% | 18.75% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $713.58M | -22.36% | -60.32% | -42.71% | -132.49% |
ROE
-41.2%
ROA
-38.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -41.20% |
| 2026-03-31 | -34.23% |
| 2025-06-30 | -343.90% |
| 2025-03-31 | -189.11% |
| 2024-12-31 | -121.56% |
| 2023-12-31 | -241.07% |
